Cover Image
Market Research Report

Specific Proteins - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 666938
Published Content info 123 Pages
Delivery time: 1-2 business days
Price
Back to Top
Specific Proteins - Medical Devices Pipeline Assessment, 2019
Published: December 1, 2019 Content info: 123 Pages
Description

GlobalData's Medical Devices sector report, "Specific Proteins - Medical Devices Pipeline Assessment, 2019" provides an overview of Specific Proteins currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Specific Proteins pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Specific Proteins under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Specific Proteins and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Specific Proteins under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0823EPD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Introduction 9

  • 2.1 Specific Proteins Overview 9

3 Products under Development 10

  • 3.1 Specific Proteins - Pipeline Products by Stage of Development 10
  • 3.2 Specific Proteins - Pipeline Products by Territory 11
  • 3.3 Specific Proteins - Pipeline Products by Regulatory Path 12
  • 3.4 Specific Proteins - Pipeline Products by Estimated Approval Date 13

4 Specific Proteins - Pipeline Products under Development by Companies 14

  • 4.1 Specific Proteins Companies - Pipeline Products by Stage of Development 14
  • 4.2 Specific Proteins - Pipeline Products by Stage of Development 15

5 Specific Proteins Companies and Product Overview 18

  • 5.1 Abbott Diagnostics Company Overview 18
    • 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.2 Alfa Wassermann Diagnostic Technologies, LLC Company Overview 20
    • 5.2.1 Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 Amerimmune LLC Company Overview 22
    • 5.3.1 Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.4 Analyticon Biotechnologies AG Company Overview 24
    • 5.4.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.5 Beckman Coulter Inc Company Overview 29
    • 5.5.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.6 China Medical Technologies Inc (Inactive) Company Overview 37
    • 5.6.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.7 Colorado State University Company Overview 38
    • 5.7.1 Colorado State University Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.8 Fujirebio Diagnostics Inc Company Overview 39
    • 5.8.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.9 Genesis Detection Systems, Inc. Company Overview 40
    • 5.9.1 Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.10 Genome Diagnostics Pvt. Ltd. Company Overview 41
    • 5.10.1 Genome Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.11 Guanine Inc Company Overview 42
    • 5.11.1 Guanine Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.12 Hologic Inc Company Overview 43
    • 5.12.1 Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.13 Isoformix Inc Company Overview 44
    • 5.13.1 Isoformix Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.14 Kobe University Company Overview 45
    • 5.14.1 Kobe University Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.15 Ortho-Clinical Diagnostics Inc Company Overview 46
    • 5.15.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.16 Ottawa Hospital Research Institute Company Overview 49
    • 5.16.1 Ottawa Hospital Research Institute Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.17 Roche Diagnostics International Ltd Company Overview 50
    • 5.17.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.18 Sebia SA Company Overview 57
    • 5.18.1 Sebia SA Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.19 Siemens Healthcare Diagnostics Inc Company Overview 58
    • 5.19.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.20 Siemens Healthineers AG Company Overview 66
    • 5.20.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.21 The Binding Site Group Ltd Company Overview 68
    • 5.21.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.22 Umea University Company Overview 69
    • 5.22.1 Umea University Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.23 University of California Company Overview 70
    • 5.23.1 University of California Pipeline Products & Ongoing Clinical Trials Overview 70

6 Specific Proteins- Recent Developments 71

  • 6.1 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 71
  • 6.2 Oct 29, 2019: ELITechGroup announces direct sales and customer support in Canada 72
  • 6.3 Oct 23, 2019: bioMerieux - Third-Quarter 2019 Business Review 72
  • 6.4 Oct 22, 2019: bioMerieux - Third quarter 2019 business review 74
  • 6.5 Oct 21, 2019: SomaLogic significantly expands key strategic collaboration with Novartis 75
  • 6.6 Oct 16, 2019: Abbott reports third-quarter 2019 results 76
  • 6.7 Oct 01, 2019: Opthea receives A$14.6mR&D tax incentive 78
  • 6.8 Sep 04, 2019: bioMerieux announces First-Half 2019 Results 79
  • 6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 82
  • 6.10 Aug 21, 2019: PerkinElmer announces leadership succession plan 83

7 Appendix 120

  • 7.1 Methodology 120
  • 7.2 About GlobalData 123
  • 7.3 Contact Us 123
  • 7.4 Disclaimer 123

List of Tables

  • Table 1: Specific Proteins - Pipeline Products by Stage of Development 11
  • Table 2: Specific Proteins - Pipeline Products by Territory 12
  • Table 3: Specific Proteins - Pipeline Products by Regulatory Path 13
  • Table 4: Specific Proteins - Pipeline Products by Estimated Approval Date 14
  • Table 5: Specific Proteins Companies - Pipeline Products by Stage of Development 15
  • Table 6: Specific Proteins - Pipeline Products by Stage of Development 17
  • Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 8: Alinity c Assay - Cystatin C - Product Status 20
  • Table 9: Alinity c Assay - Cystatin C - Product Description 20
  • Table 10: Alinity c Assay - Immunoglobulin E - Product Status 21
  • Table 11: Alinity c Assay - Immunoglobulin E - Product Description 21
  • Table 12: Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 13: ACE Axcel System - Lp(a) Assay - Product Status 22
  • Table 14: ACE Axcel System - Lp(a) Assay - Product Description 22
  • Table 15: ACE Axcel System - Microalbumin Assay - Product Status 23
  • Table 16: ACE Axcel System - Microalbumin Assay - Product Description 23
  • Table 17: ACE Axcel System - Transferrin Assay - Product Status 23
  • Table 18: ACE Axcel System - Transferrin Assay - Product Description 23
  • Table 19: Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 20: FoxP3 Protein Expression Assay - Product Status 25
  • Table 21: FoxP3 Protein Expression Assay - Product Description 25
  • Table 22: Wiscott-Aldrich Protein Expression Assay - Product Status 26
  • Table 23: Wiscott-Aldrich Protein Expression Assay - Product Description 26
  • Table 24: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 25: Turbitex C 3c Reagent - Product Status 27
  • Table 26: Turbitex C 3c Reagent - Product Description 28
  • Table 27: Turbitex C 4 Reagent - Product Status 28
  • Table 28: Turbitex C 4 Reagent - Product Description 29
  • Table 29: Turbitex CRP Reagent - Product Status 29
  • Table 30: Turbitex CRP Reagent - Product Description 30
  • Table 31: Turbitex CRP Ultra Reagent - Product Status 30
  • Table 32: Turbitex CRP Ultra Reagent - Product Description 31
  • Table 33: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 34: Access - sFlt-1 Assay - Product Status 33
  • Table 35: Access - sFlt-1 Assay - Product Description 33
  • Table 36: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Status 33
  • Table 37: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Description 33
  • Table 38: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Status 34
  • Table 39: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Description 34
  • Table 40: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Status 34
  • Table 41: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Description 34
  • Table 42: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Status 35
  • Table 43: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Description 35
  • Table 44: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Status 35
  • Table 45: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Description 36
  • Table 46: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Status 36
  • Table 47: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Description 36
  • Table 48: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Status 37
  • Table 49: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Description 37
  • Table 50: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Status 37
  • Table 51: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Description 37
  • Table 52: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Status 38
  • Table 53: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Description 38
  • Table 54: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Status 38
  • Table 55: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Description 38
  • Table 56: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Status 39
  • Table 57: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Description 39
  • Table 58: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Status 39
  • Table 59: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Description 40
  • Table 60: UniCel DxI 860i Synchron Access Clinical System - PlGF Assay - Product Status 40

List of Figures

  • Figure 1: Specific Proteins - Pipeline Products by Stage of Development 10
  • Figure 2: Specific Proteins - Pipeline Products by Territory 11
  • Figure 3: Specific Proteins - Pipeline Products by Regulatory Path 12
  • Figure 4: Specific Proteins - Pipeline Products by Estimated Approval Date 13
Back to Top